FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1069-1070 October 3, 1996 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by de Groen, P. C. PubMed Citation

To the Editor: Post-marketing reports of severe esophagitis associated with the use of alendronate sodium, reported in this issue of the Journal by de Groen et al.,¹ prompted us to reexamine in detail adverse esophageal effects in our three-year osteoporosis studies (Nov. 30, 1995, issue).² In these studies, 994 patients were randomly assigned to receive placebo, 5 or 10 mg of alendronate daily for three years, or 20 mg of alendronate for two years followed by 5 mg daily in year 3 (ratio of assignments to the four groups, 2:1:1:1, respectively). We used the same terms suggesting esophageal irritation that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Brown, J. P., Josse, R. G. (2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ 168: SF1-38 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: s1-34 [Abstract] [Full Text]  
• Dobrucali, A., Tobey, N. A., Awayda, M. S., Argote, C., Abdulnour-Nakhoul, S., Shao, W., Orlando, R. C. (2002). Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 283: G576-G586 [Abstract] [Full Text]  
• Graham, D. Y., Malaty, H. M. (2001). Alendronate and Naproxen Are Synergistic for Development of Gastric Ulcers. Arch Intern Med 161: 107-110 [Abstract] [Full Text]  
• O'Donnell, J. (2000). Drug-Induced Esophagitis. Journal of Pharmacy Practice 13: 290-296 [Abstract]  
• Bauer, D. C., Black, D., Ensrud, K., Thompson, D., Hochberg, M., Nevitt, M., Musliner, T., Freedholm, D., for the Fracture Intervention Trial Research Group, (2000). Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial. Arch Intern Med 160: 517-525 [Abstract] [Full Text]  
• Ragsdale, A. B., Barringer III, T. A., Anastasio, G. D. (1998). Alendronate Treatment to Prevent Osteoporotic Fractures. Arch Fam Med 7: 583-586 [Abstract] [Full Text]  
• de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., Wang, K. K. (1996). Esophagitis Associated with the Use of Alendronate. NEJM 335: 1016-1021 [Abstract] [Full Text]  
• Castell, D. O. (1996). "Pill Esophagitis" -- The Case of Alendronate. NEJM 335: 1058-1059 [Full Text]